MW: 465.52. Purity ≥98% by HPLC. Acalabrutinib (ACP-196) is an orally available; selective irreversible inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It is a second generation BTK inhibitor with improved pharmacological properties with better plasma exposure; oral absorption and shorter half-life. It prevents the activation of B-cell antigen receptor (BCR) signaling pathway; thus preventing B-cell activation and BTK mediated activation of downstream survi